Aarif Mohamed Nazeer Batcha

Aarif Mohamed Nazeer Batcha

Auto-generated profile, based on publicly available information

Aarif Mohamed Nazeer Batcha

Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2017 in Haematologica
Verified
Journal Article
Open access
PDF file
THTobias Herold
Tobias Herold
VJVindi Jurinovic
Vindi Jurinovic
ABAarif M. N. Batcha
Aarif M. N. Batcha
SBStefanos A. Bamopoulos
Stefanos A. Bamopoulos
MRMaja Rothenberg-Thurley
Maja Rothenberg-Thurley
KSKarsten Spiekermann
Karsten Spiekermann
Primary therapy resistance is a major problem in acute myeloid leukemia treatment. We set out to develop a powerful and robust predictor for therapy resistance for intensively treated adult patients. We used two large gene expression data sets (n=856) to develop a predictor of therapy resistance, which was validated in an independent cohort analyzed by RNA sequencing (n=250). In addition to gene expression markers, standard clinical and laboratory variables as well as the mutation status of 68 genes were considered during construction of the model. The final predictor (PS29MRC) consisted of 29 gene expression markers and a cytogenetic risk classification. A continuous predictor is calculated as a weighted linear sum of the individual variables. In addition, a cut off was defined to divide patients into a high-risk and a low-risk group for resistant disease. PS29MRC was highly significant in the validation set, both as a continuous score (OR=2.39, P=8.63·10−9, AUC=0.76) and as a dichotomous classifier (OR=8.03, P=4.29·10−9); accuracy was 77%. In multivariable models, only TP53 mutation, age and PS29MRC (continuous: OR=1.75, P=0.0011; dichotomous: OR=4.44, P=0.00021) were left as significant variables. PS29MRC dominated all models when compared with currently used predictors, and also predicted overall survival independently of established markers. When integrated into the European LeukemiaNet (ELN) 2017 genetic risk stratification, four groups (median survival of 8, 18, 41 months, and not reached) could be defined (P=4.01·10−10). PS29MRC will make it possible to design trials which stratify induction treatment according to the probability of response, and refines the ELN 2017 classification.

10 July 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
KSKatrin Schranz
Katrin Schranz
MHMax Hubmann
Max Hubmann
EHEgor Harin
Egor Harin
SVSebastian Vosberg
Sebastian Vosberg
THTobias Herold
Tobias Herold
PGPhilipp Greif
Philipp Greif
Clonal heterogeneity of FLT3 -ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia

15 July 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GAGovardhan Anande
Govardhan Anande
NDNandan P. Deshpande
Nandan P. Deshpande
SMSylvain Mareschal
Sylvain Mareschal
ABAarif M.N. Batcha
Aarif M.N. Batcha
HHHenry R. Hampton
Henry R. Hampton
JPJohn E. Pimanda
John E. Pimanda
Purpose: RNA splicing is a fundamental biological process that generates protein diversity from a finite set of genes. Recurrent somatic mutations of splicing factor genes are common in some hematologic cancers but are relatively uncommon in acute myeloid leukemia (AML, < 20% of patients). We examined whether RNA splicing differences exist in AML, even in the absence of splicing factor mutations. Experimental Design: We developed a bioinformatics pipeline to study alternative RNA splicing in RNA-sequencing data from large cohorts of patients with AML. Results: We have identified recurrent differential alternative splicing between patients with poor and good prognosis. These splicing events occurred even in patients without any discernible splicing factor mutations. Alternative splicing recurrently occurred in genes with specific molecular functions, primarily related to protein translation. Developing tools to predict the functional impact of alternative splicing on the translated protein, we discovered that approximately 45% of the splicing events directly affected highly conserved protein domains. Several splicing factors were themselves misspliced and the splicing of their target transcripts were altered. Studying differential gene expression in the same patients, we identified that alternative splicing of protein translation genes in ELNAdv patients resulted in the induction of an integrated stress response and upregulation of inflammation-related genes. Finally, using machine learning techniques, we identified a splicing signature of four genes which refine the accuracy of existing risk prognosis schemes and validated it in a completely independent cohort. Conclusions: Our discoveries therefore identify aberrant alternative splicing as a molecular feature of adverse AML with clinical relevance. See related commentary by Bowman, p. 3503

1 August 2019 in Haematologica
Verified
Journal Article
Open access
VVVijaya Pooja Vaikari
Vijaya Pooja Vaikari
YDYang Du
Yang Du
SWSharon Wu
Sharon Wu
TZTian Zhang
Tian Zhang
KMKlaus Metzeler H Metzeler
Klaus Metzeler H Metzeler
HAHouda Alachkar
Houda Alachkar
In an effort to identify target genes in acute myeloid leukemia (AML), we compared gene expression profiles between normal and AML cells from various publicly available datasets. We identified CD99, a gene that is up-regulated in AML patients. In 186 patients from The Cancer Genome Atlas AML dataset, CD99 was over-expressed in patients with FLT3-ITD and was down-regulated in patients with TP53 mutations. CD99 is a trans-membrane protein expressed on leukocytes and plays a role in cell adhesion, trans-endothelial migration, and T-cell differentiation. The CD99 gene encodes two isoforms with distinct expression and functional profiles in both normal and malignant tissues. Here we report that, although the CD99 long isoform initially induces an increase in cell proliferation, it also induces higher levels of reactive oxygen species, DNA damage, apoptosis and a subsequent decrease in cell viability. In several leukemia murine models, the CD99 long isoform delayed disease progression and resulted in lower leukemia engraftment in the bone marrow. Furthermore, the CD99 monoclonal antibody reduced cell viability, colony formation, and cell migration, and induced cell differentiation and apoptosis in leukemia cell lines and primary blasts. Mechanistically, CD99 long isoform resulted in transient induction followed by a dramatic decrease in both ERK and SRC phosphorylation. Altogether, our study provides new insights into the role of CD99 isoforms in AML that could potentially be relevant for the preclinical development of CD99 targeted therapy.

26 July 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RHRoman Hornung
Roman Hornung
VJVindi Jurinovic
Vindi Jurinovic
ABAarif M. N. Batcha
Aarif M. N. Batcha
SBStefanos A. Bamopoulos
Stefanos A. Bamopoulos
MRMaja Rothenberg-Thurley
Maja Rothenberg-Thurley
ABAnne-Laure Boulesteix
Anne-Laure Boulesteix
Alterations of RUNX1 in acute myeloid leukemia (AML) are associated with either a more favorable outcome in the case of the RUNX1/RUNX1T1 fusion or unfavorable prognosis in the case of point mutations. In this project we aimed to identify genes responsible for the observed differences in outcome that are common to both RUNX1 alterations. Analyzing four AML gene expression data sets (n = 1514), a total of 80 patients with RUNX1/RUNX1T1 and 156 patients with point mutations in RUNX1 were compared. Using the statistical tool of mediation analysis we identified the genes CD109, HOPX, and KIAA0125 as candidates for mediator genes. In an analysis of an independent validation cohort, KIAA0125 again showed a significant influence with respect to the impact of the RUNX1/RUNX1T1 fusion. While there were no significant results for the other two genes in this smaller validation cohort, the observed relations linked with mediation effects (i.e., those between alterations, gene expression and survival) were almost without exception as strong as in the main analysis. Our analysis demonstrates that mediation analysis is a powerful tool in the identification of regulative networks in AML subgroups and could be further used to characterize the influence of genetic alterations.

1 January 2015 in Cancer Informatics
Verified
Journal Article
Open access
JLJian Li
Jian Li
ABAarif Mohamed Nazeer Batcha
Aarif Mohamed Nazeer Batcha
BGBjörn Gaining
Björn Gaining
UMUlrich R. Mansmann
Ulrich R. Mansmann
Next-generation sequencing (NGS) technologies that have advanced rapidly in the past few years possess the potential to classify diseases, decipher the molecular code of related cell processes, identify targets for decision-making on targeted therapy or prevention strategies, and predict clinical treatment response. Thus, NGS is on its way to revolutionize oncology. With the help of NGS, we can draw a finer map for the genetic basis of diseases and can improve our understanding of diagnostic and prognostic applications and therapeutic methods. Despite these advantages and its potential, NGS is facing several critical challenges, including reduction of sequencing cost, enhancement of sequencing quality, improvement of technical simplicity and reliability, and development of semiautomated and integrated analysis workflow. In order to address these challenges, we conducted a literature research and summarized a four-stage NGS workflow for providing a systematic review on NGS-based analysis, explaining the strength and weakness of diverse NGS-based software tools, and elucidating its potential connection to individualized medicine. By presenting this four-stage NGS workflow, we try to provide a minimal structural layout required for NGS data storage and reproducibility.